📈 Since 2018, 56 biotech companies have been listed on the Hong Kong stock exchange through the Ch18A pathway, a special listing segment designed to accommodate high-growth, pre-revenue biotech firms. However, a recent article reveals that only 9 of these companies have been able to meet the profit requirement of LR 8.05. This raises questions about […]